BioSpace News Archive

OncoResponse, a clinical-stage biotech company advancing immunotherapies derived from the immune systems of elite cancer responders, announced the appointments of Miriam Merad, MD, PhD, and David G. DeNardo, PhD, to the company’s scientific advisory board.

Aspen Neuroscience, Inc., a private biotechnology company developing the first autologous neuron replacement therapies to treat Parkinson’s disease, announced that Kameel Farag has joined the company as Chief Financial Officer and as a member of the company’s executive team.

I-Mab (Nasdaq: IMAB), and ABL Bio, Inc. (Kosdaq:298380, hereafter “ABL”), a clinical-stage biotech developing bispecific antibody technology for immune-oncology and neurodegenerative diseases, today jointly announced preclinical data of their 4-1BB bispecific antibodies at the 2021 Society for Immunotherapy of Cancer (SITC) Annual Meeting.

Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema (HAE), today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will present a corporate overview and provide information on lead program STAR-0215 at the upcoming virtual Jefferies London Healthcare Conference.

Xalud Therapeutics today announced the appointment of Charles Triano as its chief financial officer.

U.S. Urology Partners today announced that Corina Tracy will assume the position of Chief Executive Officer effective January 1, 2022.

EPI Health, LLC and MC2 Therapeutics announced that Express Scripts, a large pharmacy benefit manager has provided access to Wynzora® Cream for once-daily topical treatment of plaque psoriasis in adults 18 years of age or older on its National Preferred, National Preferred Flex, High Performance, and Basic formularies.

Surface Oncology (Nasdaq: SURF), today announced that two scientific posters sharing updated preclinical data from Surface Oncology’s two lead clinical-stage antibody therapies, SRF617 (targeting CD39) and SRF388 (targeting IL-27), will be presented at the Society for Immunotherapy of Cancer (SITC) 2021 Annual Meeting.

Bicycle Therapeutics plc (NASDAQ: BCYC), today announced that preclinical data for BT7480, a novel Bicycle tumor-targeted immune cell agonist™ (Bicycle TICA), and BT7455, an EphA2/CD137 Bicycle TICA, will be presented in four poster presentations at the Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting.

Horizon Therapeutics plc (Nasdaq: HZNP) today announced the first patient has enrolled in a Phase 2b pivotal trial to evaluate its development-stage medicine HZN-825, a lysophosphatidic acid receptor 1 (LPAR1) antagonist to treat people with diffuse cutaneous systemic sclerosis, a subset of systemic sclerosis (also known as scleroderma).